



Express Mail No. EL 168 271 715 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jove et al.

RECEIVED

FEB 04 2002

Application No.: 09/492,764

Group Art Unit: 1642

TECH CENTER 1600/290

Filed: January 27, 2000

Examiner: Rawlings, S.

For: INHIBITION OF STAT3 SIGNAL
TRANSDUCTION FOR HUMAN
CANCER THERAPY

Atty. Docket No.: 10873-008
(formerly 114205.1101)

RESPONSE AND AMENDMENT UNDER 37 C.F.R. § 1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent

Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed April 26, 2001 in connection with the above-identified application, and in accordance with Rule 111 of the Rules of Practice, please enter the following amendments and consider the following remarks. Applicants submit concurrently herewith: (a) a copy of the Notice To Comply With Requirements for Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures; (b) a Response to the Notice To Comply With Requirements for Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures; (c) a Sequence Listing in paper and computer readable form pursuant to 37 C.F.R. §§1.821(c), (d), and (e); (d) a Transmittal of Sequence Listing; and (e) Exhibit A, a marked up version of the specification paragraphs showing the amendments made herein; (f) Exhibit B, a clean copy of the specification paragraphs, as amended; and (g) a Petition For Extension of Time from May 26, 2001 to and including October 26, 2001 including authorization and payment of the